- Home
- AARD vs VACI Comparison
AARD vs VACI Comparison
Compare AARD & VACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$15.33
N/A
Current Price
$9.93
Company Overview
Basic Information| Metric | AARD | VACI |
|---|---|---|
| Founded | 2017 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.2M | 311.1M |
| IPO Year | 2025 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AARD | VACI |
|---|---|---|
| Price | $15.33 | $9.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $31.11 | N/A |
| AVG Volume (30 Days) | ★ 214.6K | 58.5K |
| Earning Date | 02-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.88 | $9.86 |
| 52 Week High | $19.58 | $10.07 |
Technical Indicators
Market Signals| Indicator | AARD | VACI |
|---|---|---|
| Relative Strength Index (RSI) | 64.95 | N/A |
| Support Level | $14.25 | N/A |
| Resistance Level | $16.00 | N/A |
| Average True Range (ATR) | 0.93 | 0.00 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 82.00 | 0.00 |
Price Performance
Historical Comparison AARD
VACI
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About VACI Viking Acquisition Corp. I Class A Ordinary Shares
Viking Acquisition Corp I is a blank check company.